Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 14/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | TOP2A | P11388 | 2/20 | 0.61 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.61 |
| ▸ | HTR1D | P28221 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8197880 | 0.98 | NISCH (0.69) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL13030877 | 0.89 | NISCH (0.73) | NISCHTOP2ATOP2B | |
| SCHEMBL5476725 | 0.89 | NISCH (0.79) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL8198758 | 0.84 | NISCH (0.76) | NISCH | |
| SCHEMBL8197935 | 0.82 | NISCH (0.75) | NISCH | |
| SCHEMBL8201492 | 0.81 | NISCH (0.84) | NISCHLMNARECQLTOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL8196753 | 0.80 | TOP2A (0.55) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL2518908 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL8141372 | 0.79 | NISCH (1.00) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL17826831 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119776834-A | Titanium-aluminum alloy etching solution and preparation method thereof | 湖北兴福电子材料股份有限公司 | 2025-04-08 | — | — | CN | claimed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| CN-119776834-A | Titanium-aluminum alloy etching solution and preparation method thereof | 湖北兴福电子材料股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| CN-113880780-B | Benzamidine derivative, preparation method and application | 西北农林科技大学 | 2024-10-11 | — | — | CN | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| CN-113880780-A | Benzamidine derivative, preparation method and application thereof | 西北农林科技大学 | 2022-01-04 | — | — | CN | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| EP-2608671-B1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX INC (US) | 2018-12-12 | — | — | EP | disclosed |
| EP-3064204-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx, Inc. (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9334242-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160015688-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2964028-A1 | COMPOUNDS FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014138279-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2014-09-12 | — | — | WO | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| US-3932450-A | Intermediates in the preparation of imidazo(2,1-alpha)isoindoles | SANDOZ, INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | NISCH 3272/4885LMNA 3427/4885RECQL 1894/4885 |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NISCH 3272/4885LMNA 3427/4885RECQL 1894/4885 |
| US-20160015688-A1 | COMPOUNDS FOR TREATMENT OF CANCER | BRAF, NRAS, RAF1 | NISCH 2994/4885LMNA 1459/4885RECQL 909/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NISCH 3272/4885LMNA 3427/4885RECQL 1894/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | NISCH 3272/4885LMNA 3427/4885RECQL 1894/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NISCH 3272/4885LMNA 3427/4885RECQL 1894/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NISCH 3272/4885LMNA 3427/4885RECQL 1894/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NISCH 3272/4885LMNA 3427/4885RECQL 1894/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | NISCH 3272/4885LMNA 3427/4885RECQL 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.